[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521766":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":22,"locations":30,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":10,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants with myelodysplastic syndrome or beta thalassemia who will begin luspatercept treatment",null,[12],"Drug: Luspatercept",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Luspatercept","According to the approved label",[9],[20],{"name":5,"affiliation":5,"role":21},"STUDY_DIRECTOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[31,43],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Local Institution - 0001","TERMINATED","Seoul","06234","South Korea",{"type":38,"coordinates":39},"Point",[40,41],126.9784,37.566,{"lat":41,"lon":40},{"facility":44,"status":45,"city":34,"state":10,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":46,"geoPoint":48,"contacts":49},"Novotech Laboratory Korea Co., Ltd.","RECRUITING",{"type":38,"coordinates":47},[40,41],{"lat":41,"lon":40},[50],{"name":51,"role":25,"phone":52,"phoneExt":10,"email":10},"South Korea Generic Country, Site 0002","0000000000",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100521766","a-post-marketing-surveillance-study-to-assess-safety-of-luspatercept-in-korean-patients-with-myelodysplastic-syndrome-or--thalassemia-100521766",false,"NCT06073860","A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia","Reblozyl® (Luspatercept) Post-Marketing Surveillance in Korean Patients With Myelodysplastic Syndrome or Beta Thalassemia","Inclusion Criteria:\n\n* Adult participants 19 years of age or older\n* Participants who will be treated with luspatercept according to the approved label in the Republic of Korea\n* Participants who sign the informed consent form\n\nExclusion Criteria:\n\n* Participants who are prescribed luspatercept for therapeutic indications not approved in the Republic of Korea\n* Participants for whom luspatercept is contraindicated as clarified in the Korean prescribing information approved by the Ministry of Food and Drug Safety","ALL","19 Years",{"count":65,"type":66},104,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to assess the real-world safety of luspatercept in Korean participants with myelodysplastic syndrome (MDS) or beta thalassemia. Investigators will enroll participants who will begin treatment with at least 1 dose of luspatercept.",[70,71],"Myelodysplastic Syndrome","Beta Thalassemia","2024-11-05",{"date":74,"type":75},"2024-11-06","ACTUAL",{"date":77,"type":75},"2024-03-25",{"date":79,"type":66},"2027-12-21",{"name":5,"class":6},2]